Research Paper Volume 12, Issue 18 pp 18297—18321

Glioblastoma cell differentiation trajectory predicts the immunotherapy response and overall survival of patients

class="figure-viewer-img"

Figure 7. Survival analysis, prognostic performance and risk score analysis of the GDRG-based risk score model in GBM patients. Kaplan-Meier survival analysis was performed to estimate the OS of high-risk and low-risk patients in the TCGA training cohort (A) and CGGA validation cohort (D). The high-risk groups had significantly poorer OS than the low-risk groups. Time-dependent ROC curve analysis was performed to evaluate the prognostic performance of the GDRG signature for predicting the 0.5-, 1-, 2-, and 3-year OS rates in the TCGA (B) and CGGA cohorts (E). Risk score analysis of the GDRG signatures in the TCGA (C) and CGGA (F) cohorts were calculated, and the patients were divided into either a high-risk group or a low-risk group using the median value of the risk score as the cutoff value. Upper panel: Patient survival status and time distributed by the risk score. Middle panel: Risk score curves of the GDRG signatures. Bottom panel: Heatmaps of the expression levels of the 4 GDRGs in the GBM samples. The colors from green to red indicate the gene expression levels from low to high.